Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06688799

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

A Single-Center, Open-Label, Non-Randomized, Single-Arm Clinical Study on the Treatment of Refractory Autoimmune Diseases With CD19-CAR T Cells

Sponsor: Beijing GoBroad Hospital

Conditions Autoimmune Diseases

Interventions CD19 CAR-T cells

Updated 3 times since 2024 Last updated: Mar 6, 2026 Started: Nov 23, 2024 Primary completion: Mar 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06688799, this PHASE1/PHASE2 trial focuses on Autoimmune Diseases and remains actively recruiting participants. Sponsored by Beijing GoBroad Hospital, it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Mar 2026 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Nov 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing GoBroad Hospital

Data source: Beijing GoBroad Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China